McKesson (MCK) Stock Forecast & Price Target

Q: What analysts cover McKesson?

McKesson has been rated by research analysts at Barclays , Citigroup , Evercore , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , TD Cowen , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$857.36 -11.90 (-1.37%)

As of 11:41 AM Eastern

Compare

McKesson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
4

Buy
14

Based on 18 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for MCK.

Consensus Price Target

$973.44
13.54% Upside

According to the 18 analysts' twelve-month price targets for McKesson, the average price target is $973.44. The highest price target for MCK is $1,085.00, while the lowest price target for MCK is $845.00. The average price target represents a forecasted upside of 13.54% from the current price of $857.36.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MCK Analyst Ratings Over Time

Type	Current Forecast 8/19/25 to 8/19/26	1 Month Ago 7/20/25 to 7/20/26	3 Months Ago 5/21/25 to 5/21/26	1 Year Ago 8/19/24 to 8/19/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	10 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$973.44	$960.53	$968.87	$719.27
Forecasted Upside	13.54% Upside	15.44% Upside	26.67% Upside	6.27% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

McKesson Stock vs. The Competition

Type	McKesson	Healthcare Companies	Broader Market
Consensus Rating Score	2.78	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	13.15% Upside	798.74% Upside	12.60% Upside
News Sentiment Rating	Very Positive News See Recent MCK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/11/2026	Wells Fargo & Company 3 of 5 stars	Stephen Baxter 4 of 5 stars	Boost Target	Equal Weight	$812.00 ➝ $933.00	+6.26%
8/7/2026	Morgan Stanley 4 of 5 stars		Reiterated Rating	Overweight
8/6/2026	Robert W. Baird 3 of 5 stars		Set Target		$1,015.00	+20.43%
8/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
8/6/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$989.00 ➝ $1,006.00	+15.47%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,050.00 ➝ $1,080.00	+23.97%
7/24/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$945.00 ➝ $1,000.00	+21.26%
7/7/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy (B) ➝ Buy (B-)
6/10/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Glen Santangelo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$1,050.00 ➝ $925.00	+16.87%
5/8/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$875.00	+15.73%
Get the Latest News and Ratings for MCK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.
5/8/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$1,107.00 ➝ $1,015.00	+37.07%
4/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
4/6/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,040.00 ➝ $1,000.00	+16.29%
3/5/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$970.00	+4.12%
3/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$1,085.00	+16.60%
2/5/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Valiquette Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$880.00 ➝ $885.00	+7.98%
11/25/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/13/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Tanquilut Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$820.00 ➝ $900.00	+17.07%
4/4/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Sundaram Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:30 AM ET.

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 17, 2026. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

Here are some ways that investors could benefit from investing in McKesson Co.:

McKesson Co. recently reported earnings per share (EPS) of $9.93, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
The company has shown a revenue increase of 7.7% compared to the same quarter last year, suggesting a positive trend in sales and market demand.
McKesson Co. has increased its quarterly dividend to $0.94 per share, reflecting a commitment to returning value to shareholders and indicating financial stability.
Analysts have set a consensus target price of around $977.00 for McKesson Co., suggesting potential upside for investors based on current market conditions.
The company has set its fiscal year 2027 EPS guidance at 44.200-45.000, indicating confidence in future earnings growth.

McKesson
Bear Case

Investors should be bearish about investing in McKesson Co. for these reasons:

McKesson Co. has a negative return on equity of 253.21%, which may raise concerns about the company's ability to generate profit from shareholders' equity.
The net margin of 1.12% is relatively low, indicating that the company retains a small portion of revenue as profit, which could limit growth potential.
Despite recent positive developments, the stock price has shown volatility, which may pose risks for investors looking for stable returns.
There has been insider selling activity, with executives divesting shares, which could signal a lack of confidence in the company's short-term prospects.
The dividend payout ratio is currently at 8.78%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.

MCK Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $973.44, with a high forecast of $1,085.00 and a low forecast of $845.00.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 13.54% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 1 downgrade by analysts.

McKesson has been rated by research analysts at Barclays, Citigroup, Evercore, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, TD Cowen, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "healthcare" companies. The consensus rating for McKesson is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MCK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With McKesson Recommendations

This page (NYSE:MCK) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

McKesson (MCK) Stock Forecast & Price Target